Navigation Links
SemBioSys signs option agreement for safflower-produced food ingredient
Date:1/29/2008

TSX symbol: SBS

CALGARY, Jan. 29 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX: SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that it has signed an option agreement with The Instituto de Agrobiotecnologia Rosario S.A. (INDEAR) based in Rosario, Argentina. INDEAR is a joint venture company formed by Bio Sidus AG S.A. and Bioceres S.A. to develop manufacturing and development capabilities for agricultural biotechnology products for South American markets. Under the terms of the agreement, INDEAR will evaluate the utility of using plant-produced chymosin for the production of cheese in South America. As per the agreement, SemBioSys will receive an option fee and will be eligible to collect an upfront license fee, possible milestone payments and royalties or other form of profit-sharing in the event INDEAR chooses to exercise their option.

"This agreement demonstrates the breadth of opportunity offered by our plant-based technology platform. The cost advantages of producing insulin and Apo AI in plants are also applicable to non-pharmaceutical products, in this case chymosin as a protein-based food processing agent," said Andrew Baum, President and CEO of SemBioSys. "Our work with chymosin is quite advanced and we believe that it offers compelling economic advantages relative to traditional sources of chymosin enzyme. We are excited at the prospect of working with INDEAR to bring this product to market in South America, subject to INDEAR's successful completion of their evaluation.

Chymosin, also called rennet, is a natural enzyme used in the production of cheese obtained originally from calve stomachs. The majority of chymosin used today is produced via fermentation. Using its proprietary plant expression system, SemBioSys has developed safflower-produced chymosin and an extraction process that it believes will allow for the production of chymosin in plants at significantly lower costs.

About SemBioSys Genetics Inc. (http://www.sembiosys.com)

Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AI, a next generation cardiovascular drug. In addition to its pharmaceutical products, SemBioSys is developing a series of non-pharmaceutical products addressing human topical, nutritional oils and animal health markets.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at http://www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.


'/>"/>
SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SemBioSys announces 2007 third quarter results
2. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
3. SemBioSys updates Apo AI development program
4. AMDL Signs 100 Strategic Cooperation Agreements in China for Its JPGreen Clinics; Gross Sales Per Each Location Could Exceed $400,000
5. Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
6. University of Maryland, Baltimore BioPark Signs Gliknik Inc. as First Tenant in Its BioInnovation Center in Building Two
7. Amic Signs Non-Exclusive License Agreement With Roche Diagnostics for Key Cardiac Marker NT-proBNP
8. Kiwa Signs Letter of Intent with Huaxing Animal Medicine
9. Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
10. Pharsight Signs Third WinNonlin(R) AutoPilot(TM) Customer
11. Martek Signs DHA/ARA License and Supply Agreement With IlDong Foodis for Infant Formula in South Korea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... (PRWEB) , ... April 27, 2016 , ... ... Touch screen mobile devices with fingerprint recognition for secure access, voice recognition ... only a few ways consumers are interacting with biometrics technology today. But ...
(Date:4/27/2016)... ... 27, 2016 , ... NDA Partners Chairman Carl Peck, ... Expert Consultant. Mr. Clark was formerly a Vice President with US Pharmacopeia, ... molecule monographs based on analytical methods. NDA Partners Expert Consultants are top ...
(Date:4/27/2016)... ... 27, 2016 , ... Global Stem Cells Group and the University ... other research and development initiatives for potential stem cell protocol management for 2016 – ... Group executives began meeting to establish a working agenda and foster initiatives to promote ...
(Date:4/26/2016)... CA (PRWEB) , ... April 26, 2016 , ... ... healthcare, today announced that Ardy Arianpour has joined the company as Chief Business ... of experience bringing innovative genomic technologies to market, was most recently Chief Commercial ...
Breaking Biology Technology:
(Date:3/29/2016)... , March 29, 2016 LegacyXChange, ... LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to announce ... used in a variety of writing instruments, ensuring athletes ... originally created collectibles from athletes on LegacyXChange will be ... of the DNA. Bill Bollander , ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... (NSO), which operates the highest sample volume laboratory in ... Tute Genomics and UNIConnect, leaders in clinical sequencing informatics ... the launch of a project to establish the informatics ... NSO has been contracted by the ...
(Date:3/17/2016)... , March 17, 2016 ABI ... intelligence, forecasts the global biometrics market will reach ... impressive 118% increase from 2015. Consumer electronics, particularly ... embedded fingerprint sensors anticipated to reach two billion ... Dimitrios Pavlakis , Research Analyst at ...
Breaking Biology News(10 mins):